Novel drug combination for Mycobacterium abscessus disease therapy identified in a Drosophila infection model | Zendy

Chun-Taek Oh | Zendy; Chéol Moon | Zendy; Ok Kyu Park | Zendy; S.-H. Kwon | Zendy; Jae Won Jang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Novel drug combination for Mycobacterium abscessus disease therapy identified in a Drosophila infection model

Author(s) -

Chun-Taek Oh,

Chéol Moon,

Ok Kyu Park,

S.-H. Kwon,

Jae Won Jang

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku024

Subject(s) - mycobacterium abscessus , tigecycline , linezolid , clarithromycin , microbiology and biotechnology , amikacin , clofazimine , medicine , rifabutin , mycobacterium , antibiotics , nontuberculous mycobacteria , moxifloxacin , biology , pharmacology , staphylococcus aureus , immunology , vancomycin , pathology , bacteria , tuberculosis , leprosy , genetics

Mycobacterium abscessus is known to be the most drug-resistant Mycobacterium and accounts for ∼80% of pulmonary infections caused by rapidly growing mycobacteria. This study reports a new Drosophila melanogaster-M. abscessus infection model that can be used as an in vivo efficacy model for anti-M. abscessus drug potency assessment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research